For some firms with large nonliquid assets, preferred shareholders can still get back a little bit of money when the firms finish disbursement of loans at the status of bankruptcy. For such a situation, to investigate the optimal dividend policy, a stochastic dynamic dividend model with nonzero terminal bankruptcy values is put forward in this paper. Moreover, an analytic solution for the optimal objective function of the discounted dividends is provided and verified. An important application of this result is that it can be employed to construct the solution for the optimal value function on the dividend problem with bailouts at bankruptcy. Further, the relationship for the solutions of these two different problems is demonstrated. In the end, some numerical examples are provided to support our theoretical results and the corresponding economic interpretations are illustrated.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2B9DDCz
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Pulmonary complications post hematopoietic stem cell transplant in dyskeratosis congenita: analysis of oxidative stress in lung fibrobl...
-
Background. Antitumor necrosis factor (anti-TNF) therapy is a highly effective but costly treatment for inflammatory bowel disease (IBD). Me...
-
Abstract Desmoplastic small round cell tumor (DSCRT) is a rare malignancy most often seen in the abdomen or pelvis of young men. Unfortuna...
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2nGQ2DC via IFTTT
-
Article content meets expectations Minimal relevance to assigned subject matter. Article content fails to meet all requirements Not Rubric f...
-
Objective To determine the association between neuroendocrine tumor (NET) biomarker levels and the extent of disease as assessed by 68 Ga DO...
-
Elementary school kids, on the other hand, can read, write, reason and think highly complex thoughts. Adele Faber and Elaine Mazlish, author...
-
by Mindaugas Paužuolis, Torsten Eich, Joachim Burman Background Natalizumab (NTZ) is a drug that has been widely used in the treatment of m...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου